Phase II Trial of TG4010 Plus Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed After One Line of Systemic Therapy
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2017
At a glance
- Drugs TG 4010 (Primary) ; Nivolumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Mar 2017 According to a Transgene media release, first results from the study could be expected from the end of 2017.
- 13 Mar 2017 According to a Transgene media release, first patient has been dosed in the study.
- 19 Dec 2016 Status changed from not yet recruiting to recruiting.